Curevax

CureVax specializes in developing cancer immunotherapeutic treatments, focusing on melanoma. Their proprietary technology involves sampling and culturing a patient's tumor cells, then using a virus to lyse and expose the cancer's vulnerabilities. The processed tumor cells, now recognized by the patient's immune system, are injected back to stimulate an immune response. This method aims to complement existing medical and surgical treatments, potentially prolonging survival and improving quality of life for patients.